LMB In The News

“The amoeboid movement by which many types of cell crawl across surfaces has fascinated scientists ever since it was first observed using the earliest microscopes. Until recently, it has remained mysterious how cells extend the thin protrusion, known as a lamellipod, that enables them to move forward. In the past decade, however, extensive experimental work has shown that amoeboid motility is associated with the regulated polymerisation of branched actin filaments within the lamellipod. Now, researchers at the London Centre for Nanotechnology and in Cambridge have developed a physical model that explains how this polymerisation generates motion. In a paper published in Proceedings of the National Academy of Sciences, Christian Schreiber (Cambridge University), Murray Stewart (MRC Laboratory of Molecular Biology) and Tom Duke (LCN) propose that the key point is that the packing efficiency of randomly oriented rod-like filaments decreases rapidly as the filaments get longer.” More…

“In a paper recently published in Genome Biology, Boris Adryan (Cambridge University) and Sarah Teichmann (LMB) have presented evidence that calls in to question currently-held beliefs about how transcription factors (TFs) coordinate gene expression during development to specify the fates of the different tissues in the body.” More…

“On the night he learned he’d won the 1962 Nobel Prize, legend has it that DNA co-discoverer Francis Crick threw himself quite a party: angry neighbors, cops, the works. One of the guests, it seems, had brought a large supply of fireworks to the event, and the ensuing late-night mayhem was rocking the sleepy streets of Cambridge. That guest was Hildegard Lamfrom, an American biochemist from California Institute of Technology, who was working with Crick and several other future Nobel laureates at the Medical Research Council Laboratory of Molecular Biology in Cambridge. Lamfrom was known for her love of a lively party, but she was better known during the late 1950s and early 1960s as one of the sharpest, most tenacious bench scientists in the burgeoning field of molecular biology.” This article is no longer available from the source website: Oregon Health & Science University, 30 April 2010

“Bicycle Therapeutics Ltd, a new biotechnology company developing a novel technology platform for the identification and optimisation of chemically constrained cyclic peptides with high target specificity and binding affinity, has signed a License agreement with the Ecole Polytechnique Federale de Lausanne (EPFL) in Lausanne, Switzerland and has secured additional seed funding from SR One, the independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences. Bicycle Therapeutics is a spin-out from the MRC Laboratory of Molecular Biology, Cambridge and is based at the Babraham Research Campus in Cambridge, UK.” More…

“Scientists say some viruses can turn cells into ‘viral hotels’ by exploiting tiny molecules derived from human DNA. The UK study [directed by Cancer Research UK and in collaboration with LMB] found that some viruses can boost microRNA activity to suppress the immune system’s reaction to them.” More…

“Researchers are taking advantage of new tools and techniques in imaging, sequencing, and proteomics to zoom in on what single cells are doing … Paul Dear at the MRC Laboratory of Molecular Biology says that single-cell analysis is going to explode — and test the paradigm that all cells in a body have identical genomes. “I think we are going to see a lot more cell-cell variation,” he says. Right now, though, Dear is focusing on cancer as those individual cells have lots of genomic differences.” More…